| Name | Title | Contact Details |
|---|
OrthoSupply Management is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mangrove Bay Dentistry is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GDM's VACS software provides capture capabilities and collaborative tools using typically un-captured but critical visual information between patients, clinicians and medical specialists. VACS helps solve the problems today’s clinicians face relating to increased patient flow, less time available and increased demand for better outcomes. The VACS platform, which includes proprietary management software, digital capture/streaming and mobile applications, provides a new level of “rich media” capture, access, interaction and use of images, video, audio and other data elements. Management is currently focused on expanding the VACS platform internationally, to increase clinical efficiency and bridge the visual information gap in today’s growing clinical collaboration processes
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk PCI and cardiogenic shock.